Search results for "PI3K"

showing 10 items of 240 documents

Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy

2012

An area of therapeutic interest in cancer biology and treatment is targeting the cancer stem cell, more appropriately referred to as the cancer initiating cell (CIC). CICs comprise a subset of hierarchically organized, rare cancer cells with the ability to initiate cancer in xenografts in genetically modified murine models. CICs are thought to be responsible for tumor onset, self-renewal/maintenance, mutation accumulation and metastasis. CICs may lay dormant after various cancer therapies which eliminate the more rapidly proliferating bulk cancer (BC) mass. However, CICs may remerge after therapy is discontinued as they may represent cells which were either intrinsically resistant to the or…

PTENgerminal mutationchemotherapeuticmedicine.medical_treatmentAntineoplastic AgentsPI3KTargeted therapyMetastasisMice03 medical and health sciencesTARGETED THERAPY0302 clinical medicineCancer stem cellNeoplasmsradiologicalDrug DiscoverymedicineAnimalsHumansPTENAkt; mTOR; PI3K; PTEN; Targeted therapy; Therapeutic sensitivityPI3K/AKT/mTOR pathway030304 developmental biologyPharmacologyBiological Products0303 health sciencesbiologyAKTMTORAktCD44Wnt signaling pathwayCancertargeted therapymedicine.disease3. Good healththerapeutic sensitivityxenografts030220 oncology & carcinogenesisImmunologymTORNeoplastic Stem CellsCancer researchbiology.proteinCurrent Pharmaceutical Design
researchProduct

The immunosuppressive activity of artemisinin‐type drugs towards inflammatory and autoimmune diseases

2021

The sesquiterpene lactone artemisinin from Artemisia annua L. is well established for malaria therapy, but its bioactivity spectrum is much broader. In this review, we give a comprehensive and timely overview of the literature regarding the immunosuppressive activity of artemisinin-type compounds toward inflammatory and autoimmune diseases. Numerous receptor-coupled signaling pathways are inhibited by artemisinins, including the receptors for interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α), β3-integrin, or RANKL, toll-like receptors and growth factor receptors. Among the receptor-coupled signal transducers are extracellular signal-regulated protein kinase (ERK), c-Jun N-terminal kinas…

PharmacologyMAPK/ERK pathwaybiologybusiness.industryNF-kappa BArtemisinins570 Life sciencesAutoimmune DiseasesAP-1 transcription factorGrowth factor receptorRANKLDrug DiscoveryCancer researchbiology.proteinHumansMolecular MedicineMedicineSignal transductionbusinessProtein kinase AProtein kinase BImmunosuppressive AgentsPI3K/AKT/mTOR pathway570 BiowissenschaftenSignal TransductionMedicinal Research Reviews
researchProduct

The Synergistic Effect of SAHA and Parthenolide in MDA-MB231 Breast Cancer Cells

2015

The sesquiterpene lactone Parthenolide (PN) exerted a cytotoxic effect on MDA-MB231 cells, a triple-negative breast cancer (TNBC) cell line, but its effectiveness was scarce when employed at low doses. This represents an obstacle for a therapeutic utilization of PN. In order to overcome this difficulty we associated to PN the suberoylanilide hydroxamic acid (SAHA), an histone deacetylase inhibitor. Our results show that SAHA synergistically sensitized MDA-MB231 cells to the cytotoxic effect of PN. It is noteworthy that treatment with PN alone stimulated the survival pathway Akt/mTOR and the consequent nuclear translocation of Nrf2, while treatment with SAHA alone induced autophagic activity…

Physiologymedicine.drug_classClinical BiochemistryHistone deacetylase inhibitorCaspase 3Cell Biologychemistry.chemical_compoundchemistryBiochemistryApoptosismedicineCancer researchCytotoxic T cellParthenolideVorinostatProtein kinase BPI3K/AKT/mTOR pathwaymedicine.drugJournal of Cellular Physiology
researchProduct

Docosahexaenoic acid protects human RPE cells against oxidative stress via PI3K/Akt m-TOR/p70-p85S6K pathways

2012

Purpose Oxidative Stress (OS) plays a critical role in the pathogenesis of age-related macular degeneration (AMD), especially by targeting the retinal pigment epithelium (RPE). Dietary habits with high consumption of docosahexaenoic acid (DHA) have been shown to prevent the development and evolution of AMD. Nevertheless, it is still unclear how DHA affects AMD. Our study aimed to investigate the involvement of the PI3K/Akt and m-TOR/p70-p85S6K pathways in human RPE cells after induction of OS, and then to assess the effect of DHA in the signaling pathways and in the protection against RPE cell death. Methods For this purpose, we used ARPE-19 cells exposed to the prooxidant agent, tert-butyl…

Programmed cell deathmacular degenerationP70-S6 Kinase 1Biologymedicine.disease_cause03 medical and health sciences0302 clinical medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologymedicineoxidative stress[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansProtein kinase BPI3K/AKT/mTOR pathway030304 developmental biology0303 health sciencesacide docosahexaénoiquestress oxydatifGeneral Medicinedégénérescence maculaireeye diseasesCell biologyOphthalmologyDocosahexaenoic acidBiochemistryDocosahexaenoic acidApoptosis030220 oncology & carcinogenesis[ SDV.MHEP.OS ] Life Sciences [q-bio]/Human health and pathology/Sensory OrgansPhosphorylationsense organsOxidative stress[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT.

2011

International audience; BACKGROUND: TRAIL/Apo2L is a pro-apoptotic ligand of the TNF family that engages the apoptotic machinery through two pro-apoptotic receptors, TRAIL-R1 and TRAIL-R2. This cell death program is tightly controlled by two antagonistic receptors, TRAIL-R3 and TRAIL-R4, both devoid of a functional death domain, an intracellular region of the receptor, required for the recruitment and the activation of initiator caspases. Upon TRAIL-binding, TRAIL-R4 forms a heteromeric complex with the agonistic receptor TRAIL-R2 leading to reduced caspase-8 activation and apoptosis. METHODOLOGY/PRINCIPAL FINDINGS: We provide evidence that TRAIL-R4 can also exhibit, in a ligand independent…

Proliferation indexlcsh:MedicineTNF-Related Apoptosis-Inducing LigandHeLaMicePhosphatidylinositol 3-Kinases0302 clinical medicineMolecular Cell BiologyBasic Cancer ResearchMembrane Receptor SignalingEnzyme Inhibitorslcsh:SciencePhosphoinositide-3 Kinase Inhibitors0303 health sciencesMultidisciplinaryCell Deathbiologyapoptosis3. Good healthCell biologyOncology030220 oncology & carcinogenesisMedicineFemaleSignal transductionResearch ArticleSignal TransductionProgrammed cell deathMorpholinesproliferationBlotting WesternMice Nude03 medical and health sciencesTRAIL-R4[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologyAnimalsHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyBiology[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyProtein kinase BPI3K/AKT/mTOR pathwayCell Proliferation030304 developmental biologyCell growthAktCell Membranelcsh:RPTEN PhosphohydrolaseNeoplasms Experimentalbiology.organism_classificationTumor Necrosis Factor Decoy ReceptorsChromonesApoptosislcsh:QProto-Oncogene Proteins c-aktHeLa Cells
researchProduct

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast can…

2010

Introduction Accumulating evidence suggests that both levels and activity of the estrogen receptor (ER) and the progesterone receptor (PR) are dramatically influenced by growth-factor receptor (GFR) signaling pathways, and that this crosstalk is a major determinant of both breast cancer progression and response to therapy. The phosphatidylinositol 3-kinase (PI3K) pathway, a key mediator of GFR signaling, is one of the most altered pathways in breast cancer. We thus examined whether deregulated PI3K signaling in luminal ER+ breast tumors is associated with ER level and activity and intrinsic molecular subtype. Methods We defined two independent molecular signatures of the PI3K pathway: a pro…

ProteomeMessengerEstrogen receptorPhosphatidylinositol 3-Kinases0302 clinical medicineReceptorsTumor Cells CulturedInsulin-Like Growth Factor IReceptorCancerOligonucleotide Array Sequence AnalysisMedicine(all)0303 health sciencesCulturedTumorBlottingReverse Transcriptase Polymerase Chain ReactionPrognosis3. Good healthTumor CellsGene Expression Regulation NeoplasticReceptors Estrogen030220 oncology & carcinogenesisFemaleSignal transductionWesternmedicine.drugBiotechnologySignal TransductionResearch Articlemedicine.medical_specialtyBlotting WesternOncology and CarcinogenesisBreast NeoplasmsBiology03 medical and health sciencesInternal medicineProgesterone receptorBreast CancerBiomarkers TumormedicineGeneticsHumansRNA MessengerOncology & CarcinogenesisPI3K/AKT/mTOR pathway030304 developmental biologyCell ProliferationNeoplasticCell growthGene Expression ProfilingEstrogenGene expression profilingEndocrinologyGene Expression RegulationCancer researchRNAProto-Oncogene Proteins c-aktTamoxifenBiomarkersBreast Cancer Research : BCR
researchProduct

Syntaxin13 expression is regulated by mammalian target of rapamycin (mTOR) in injured neurons to promote axon regeneration.

2014

Injured peripheral neurons successfully activate intrinsic signaling pathways to enable axon regeneration. We have previously shown that dorsal root ganglia (DRG) neurons activate the mammalian target of rapamycin (mTOR) pathway following injury and that this activity enhances their axon growth capacity. mTOR plays a critical role in protein synthesis, but the mTOR-dependent proteins enhancing the regenerative capacity of DRG neurons remain unknown. To identify proteins whose expression is regulated by injury in an mTOR-dependent manner, we analyzed the protein composition of DRGs from mice in which we genetically activated mTOR and from mice with or without a prior nerve injury. Quantitati…

ProteomicsAxon; Proteomics; Regeneration; SNARE Proteins; mTORSNARE Proteinmedicine.medical_treatmentInbred C57BLRegenerative MedicineBiochemistryMedical and Health SciencesMiceNeurobiologyGanglia SpinalAxonCells CulturedMice KnockoutGene knockdownCulturedQa-SNARE ProteinsTOR Serine-Threonine KinasesAxotomyBiological SciencesSciatic NerveCell biologymedicine.anatomical_structureNeurologicalmTORFemaleAxotomySignal transductionmedicine.symptomSNARE ProteinsBiochemistry & Molecular BiologyPhysical Injury - Accidents and Adverse EffectsSpinalSensory Receptor CellsCellsKnockout1.1 Normal biological development and functioningBiologyAxonUnderpinning researchmedicineAnimalsRegenerationMolecular BiologyPI3K/AKT/mTOR pathwayRegeneration (biology)NeurosciencesProteomicCell BiologyNerve injuryAxonsNerve RegenerationMice Inbred C57BLnervous systemChemical SciencesAxoplasmic transportGanglia
researchProduct

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

2008

Abstract Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in cancer. By applying mass spectroscopy–based sequencing and reverse-phase protein arrays to 547 human breast cancers and 41 cell lines, we determined the subtype specificity and signaling effects of PIK3CA, AKT, and PTEN mutations and the effects of PIK3CA mutations on responsiveness to PI3K inhibition in vitro and on outcome after adjuvant tamoxifen. PIK3CA mutations were more common in hormone receptor–positive (34.5%) and HER2-positive (22.7%) than in basal-like tumors (8.3%). AKT1 (1.4%) and PTEN (2.3%) mutations were restricted to hormone receptor–positive cancers. Unlike AKT1 mutations that were absent …

ProteomicsCancer ResearchClass I Phosphatidylinositol 3-KinasesAKT1Breast NeoplasmsBiologymedicine.disease_causeArticlePhosphatidylinositol 3-KinasesBreast cancermedicineHumansPTENneoplasmsProtein kinase BPI3K/AKT/mTOR pathwayMutationPTEN PhosphohydrolaseCancerGenomicsmedicine.diseaseOncologyMutationCancer researchbiology.proteinFemaleProto-Oncogene Proteins c-aktCell DivisionTamoxifenmedicine.drugCancer Research
researchProduct

Longitudinal CSF proteome profiling in mice to uncover the acute and sustained mechanisms of action of rapid acting antidepressant (2R,6R)-hydroxynor…

2021

Delayed onset of antidepressant action is a shortcoming in depression treatment. Ketamine and its metabolite (2R,6R)-hydroxynorketamine (HNK) have emerged as promising rapid-acting antidepressants. However, their mechanism of action remains unknown. In this study, we first described the anxious and depression-prone inbred mouse strain, DBA/2J, as an animal model to assess the antidepressant-like effects of ketamine and HNK in vivo. To decode the molecular mechanisms mediating HNK's rapid antidepressant effects, a longitudinal cerebrospinal fluid (CSF) proteome profiling of its acute and sustained effects was conducted using an unbiased, hypothesis-free mass spectrometry-based proteomics app…

ProteomicsNeurophysiology and neuropsychologyanimal structuresHydroxynorketaminePhysiologyGlucocorticoid receptor signalingAntidepressantCSFNeurosciences. Biological psychiatry. NeuropsychiatryBiologyPharmacologyProteomicsBiochemistryCellular and Molecular NeuroscienceEndocrinologyGlucocorticoid receptorNeurotrophic factorsmedicineOriginal Research ArticleKetamine ; CSF ; Antidepressant ; (2R6R)-Hydroxynorketamine ; Glucocorticoid receptor signaling ; ProteomicsRC346-429Molecular BiologyPI3K/AKT/mTOR pathwayEndocrine and Autonomic SystemsQP351-495Mechanism of action(2R6R)-Hydroxynorketamineembryonic structuresAntidepressantKetamineNeurology. Diseases of the nervous systemmedicine.symptomSignal transductionRC321-571Neurobiology of Stress
researchProduct

ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs)

2015

Approximately 5-10% of metastatic colorectal cancers harbor a BRAF-V600E mutation, which is correlated with resistance to EGFR-targeted therapies and worse clinical outcome. Vice versa, targeted inhibition of BRAF-V600E with the selective inhibitor PLX 4032 (Vemurafenib) is severely limited due to feedback re-activation of EGFR in these tumors. Mounting evidence indicates that upregulation of the ErbB-3 signaling axis may occur in response to several targeted therapeutics, including Vemurafenib, and NRG-1β-dependent re-activation of the PI3K/AKT survival pathway has been associated with therapy resistance. Here we show that colon CSCs express, next to EGFR and ErbB-2, also significant amoun…

Proto-Oncogene Proteins B-rafMAPK/ERK pathwayIndolesReceptor ErbB-3Colorectal cancerNeuregulin-1colon cancer stem cellsMice NudeAntineoplastic AgentsMiceErbBErbB-3medicineAnimalsHumansNeuregulin 1VemurafenibClonogenic assayskin and connective tissue diseasesProtein kinase BneoplasmsPI3K/AKT/mTOR pathwayCell ProliferationOligonucleotide Array Sequence AnalysisNRG-1βSulfonamidesbiologyReverse Transcriptase Polymerase Chain Reactionbusiness.industryFlow Cytometrymedicine.diseaseImmunohistochemistryXenograft Model Antitumor AssaysVemurafenibOncologyDrug Resistance NeoplasmColonic NeoplasmsImmunologyNeoplastic Stem CellsCancer researchbiology.proteinbusinessPriority Research Papermedicine.drug
researchProduct